Home › CRISPR Model Creation › Neurodegenerative Diseases Models ›
More Disease Modeling Services
Alzheimer’s disease (AD), a severe neurodegenerative disorder, significantly impacts memory, cognition, and behavior. As research strives to decipher AD’s genetic roots and potential treatments, numerous AD-related strains have been sequenced and validated. These sequences, pinpointing common AD mutations, guide research and treatment development.
However, selecting optimal mutants for study poses challenges due to the vast array of strains, alleles, and mutation causes—including environmental influences—that produce varying disease characteristics. The researchers also struggle to ensure that the sourced strains retain their intended mutations while avoiding genetic drift. At InVivo Biosystem, we offer a range of AD models to help researchers better understand the underlying causes of AD and develop new treatments.
Our goal is to create a curated, reliable library of strains that are relevant to Alzheimer’s disease. We have carefully selected:
STRAIN
HUMAN GENE
WORM GENE HOMOLOGUE
TYPE OF TRANSGENIC
PROTEIN ACTIVITY
WORM PHENOTYPE
Fig 1. Day-2 ALZ PSEN1 Knock-out live C. elegans on NGM plate.
This worm was dyed with both RediStain™ WormDyes Lyso (magenta) and Neuro Green (cyan) to stain sensory neurons and apoptotic corpses in the gonad respectively.
The sel-12(ty11) mutation produces defects in vulva and neuronal development leading to a dysfunctional uterine-vulval connection and ultimately the inability to lay eggs. The worm is positioned head-down on the left and head-up on the right.
Video: Day-1 adult ALZ Humanized MAPT C. elegans in 5HT 10mM.
This worm immobilized into a ScreenChip Channel expresses GFP in the pharyngeal muscles under the control of the myo-2 promoter.
Ready to get started?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.
